By SPC News Staff
A generic drug for male-pattern baldness and enlarged prostate was found to reduce the long-term risk for prostate cancer by 25% in the landmark PCPT (Prostate Cancer Prevention Trial).
Long-term data showed that finasteride, a generic hormone-blocking drug, showed that the risk reduction continued, and fewer than 100 men on the trial died from the disease. The greatest effect was seen in men who undergo regular prostate-specific antigen testing (N Engl J Med